Parkinson’s disease and Huntington’s disease by PET and MRI

      Parkinson's disease (PD) and Huntington’s disease (HD) are chronic neurodegenerative disease characterized clinically by disorder of movements. The underlying mechanisms of neurodegeneration in PD and HD are still unknown, and there are no disease-modifying treatments to slow the neurodegenerative processes. There is an urgent need to identify biomarkers able to monitor disease progression and assess the development and efficacy of novel disease-modifying drugs. Over the past years, neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have provided important advances in our understanding of PD and HD. PET can detect molecular changes in the brain, and it is therefore a more specific technique to assess neurotransmitter and receptor abnormalities in PD and HD brains in vivo.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect